69464-98-8

Basic information

• Product Name: 4-BROMO-3-METHYL-1-PHENYL-1H-PYRAZOL-5-&
• Synonyms: 4-BROMO-3-METHYL-1-PHENYL-1H-PYRAZOL-5-&;4-BROMO-5-METHYL-2-PHENYL-2H-PYRAZOL-3-&;4-bromo-3-methyl-1-phenyl-1h-pyrazol-5-ylamine;5-AMino-4-broMo-3-Methyl-1-phenyl-1H-pyrazole, 97%;4-Bromo-3-methyl-1-phenyl-1H-pyrazol-5-amine;5-Amino-4-bromo-3-methyl-1-phenylpyrazole;(4-bromo-5-methyl-2-phenyl-pyrazol-3-yl)amine;4-bromo-5-methyl-2-phenyl-3-pyrazolamine
• CAS NO: 69464-98-8
• Molecular Formula: C₁₀H₁₀BrN₃
• Molecular Weight: 252.11
• EINECS: 232-784-7
• Mol File: 69464-98-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 103-107 °C(lit.)
• Boiling Point: 369.1°C at 760 mmHg
• Flash Point: 177°C
• Appearance: /
• Density: 1.57g/cm³
• Vapor Pressure: 1.21E-05mmHg at 25°C
• Refractive Index: 1.668
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-BROMO-3-METHYL-1-PHENYL-1H-PYRAZOL-5-&(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-METHYL-1-PHENYL-1H-PYRAZOL-5-&(69464-98-8)
• EPA Substance Registry System: 4-BROMO-3-METHYL-1-PHENYL-1H-PYRAZOL-5-&(69464-98-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 69464-98-8(Hazardous Substances Data)

Usage

General Description

4-Bromo-3-methyl-1-phenyl-1H-pyrazol-5-ol, also known as 4-Bromo-3-methyl-1-phenyl-1H-pyrazol-5-ol or simply BMPPP, is a chemical compound with the molecular formula C11H10BrN3O. It is a synthetic organic compound used in research and drug development. BMPPP is a pyrazolone derivative, which has been shown to have potential pharmacological activities, such as analgesic and anti-inflammatory properties. It is often used as a reference standard in analytical techniques, such as chromatography and spectrophotometry, and can also serve as a building block in the synthesis of other chemical compounds. However, it is important to handle BMPPP with caution, as it may have hazardous properties and should be stored and used according to proper safety guidelines.

InChI:InChI=1/C10H10BrN3/c1-7-9(11)10(12)14(13-7)8-5-3-2-4-6-8/h2-6H,12H2,1H3

Upstream product

• 60930-93-0 1-bromo-1-cyanopropan-2-on 
• 100-63-0 phenylhydrazine 
• 1131-18-6 1-Phenyl-3-methyl-5-aminopyrazole 

Downstream Products

• 77696-56-1 5-amino-4'-bromo-3,3'-dimethyl-4,5'-azobis-1,1'-diphenylpyrazole 
• 130645-90-8 (4-Bromo-5-methyl-2-phenyl-2H-pyrazol-3-yl)-[1-(4-dimethylamino-phenyl)-meth-(E)-ylidene]-amine 
• 76808-79-2 3,4-dimethyl-1,6-diphenyldipyrazolo<4,5-b:4',5'-c>-1,6-dihydropyridazine 

Relevant articles and documents

Metal-free ring opening of 5-amino-1,4-diaryl-1H-pyrazoles: A facile access to 2-aryl-3-arylazoacrylonitriles

Various 2-aryl-3-arylazoacrylonitriles are synthesized while attempting the intramolecular N-arylation of 5-aminopyrazoles, using the hypervalent iodine reagent. The synthesis involves phenyl iodine diacetate-assisted ring opening of 5-aminopyrazoles at r

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.